共 39 条
[1]
Nenci G(2003)Low molecular weight heparins: are they interchangeable? No J Thromb Haemost 1 12-3
[2]
Fareed J(1988)Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins Haemostasis 18 33-47
[3]
Walenga JM(1998)Low molecular weight heparins. Are they different? Can J Cardiol 14 28E-34E
[4]
Racanelli A(1999)Low molecular weight heparins: differences and similarities in approved preparations in the United States Clin Appl Thromb Hemost 5 S63-6
[5]
Hoppensteadt D(2004)Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on therapeutic the profile Curr Pharm Des 10 983-99
[6]
Huan X(2006)A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer J Thromb Haemost 4 1693-700
[7]
Messmore HL(2003)Generic forms of low-molecular-weight heparins: some practical considerations Clin Appl Thromb Hemost 9 293-7
[8]
Fareed J(2003)Are the current guidelines for the acceptance of generic low molecular weight heparins adequate? Clin Appl Thromb Hemost 9 269-72
[9]
Hoppensteadt D(2005)Generic Low Molecular Weight Heparins: A Significant Dilemma Clin Appl Thromb Hemost 11 363-66
[10]
Jeske W(undefined)undefined undefined undefined undefined-undefined